Argyrios Ginoudis

Dr. Argyrios Ginoudis

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SIStavroula Ioannidou
Stavroula Ioannidou
Magda TsolakiMagda Tsolaki
Magda Tsolaki
AGArgyrios Ginoudis
Argyrios Ginoudis
ATAndroniki Tamvakis
Androniki Tamvakis
Anthoula C. TsolakiAnthoula C. Tsolaki
Anthoula C. Tsolaki
Evgenia LymperakiEvgenia Lymperaki
Evgenia Lymperaki
Background: Reactive oxygen species (ROS) are involved in the pathophysiology of neurodegeneration and cognitive decline, indicating the potential use of oxidative stress biomarkers for early diagnosis. Mild cognitive impairment (MCI) is defined as a cognitive decline beyond normal aging, without significant impact on daily functioning, and is considered an important stage of early detection of neurodegeneration. This study aimed to investigate serum and cerebrospinal fluid (CSF) levels of oxidative stress biomarkers, total ROS and malondialdehyde (MDA) in patients with MCI to evaluate their utility in the early diagnosis of Alzheimer’s disease (AD). Levels of oxidative stress biomarkers were also assessed according to age and sex, as well as their correlation with the established CSF biomarkers, including amyloid-beta (Aβ40, Aβ42 and Aβ42/Aβ40 ratio), phosphorylated tau protein (p-tau) and total tau (t-tau). Methods: A total of 114 adults were divided into three groups: MCI (A−) patients with a normal CSF Aβ42/Aβ40 ratio (n = 38), MCI (A+) patients with an abnormal Aβ42/Aβ40 ratio (n = 38) and healthy cognitive function individuals with a normal Aβ42/Aβ40 ratio (n = 38). Established CSF biomarkers were conducted using an automated immunochemical method, while total ROS levels were measured by fluorometry and MDA levels were determined by competitive inhibition enzyme immunoassay. Results: A statistically significant difference was observed in CSF MDA levels (p < 0.05) and serum ROS levels (p < 0.05) between the study groups. Sex analysis revealed significantly higher levels of CSF MDA levels in the MCI (A+) males’ group (p < 0.05). In terms of age categorization, serum MDA levels were markedly higher in the MCI (A+) group of older patients (p < 0.01). Conclusions: These findings highlight the importance of individualized approaches, including investigation of oxidative stress biomarkers profile to prevent and manage individuals in the early stages of MCI, considering demographic factors.

Verified
Journal Article
Open access
PDF file
AGArgyrios Ginoudis
Argyrios Ginoudis
SIStavroula Ioannidou
Stavroula Ioannidou
GTGeorgia Tsakiroglou
Georgia Tsakiroglou
KKKONSTANTINA KAZELI
KONSTANTINA KAZELI
EVEleni Vagdatli
Eleni Vagdatli
Evgenia LymperakiEvgenia Lymperaki
Evgenia Lymperaki
Diabetes mellitus is a chronic metabolic disease that affects more than 10.5% of the world’s adult population. Biochemical and hematological parameters, such as albumin (ALB) and red cell distribution width (RDW), have been shown to be altered in diabetic patients. This study aimed to correlate hematological and biochemical parameters with glycated hemoglobin (HbA1c). A total of 777 adults (372 women and 405 men, aged 19–85 years) were divided into three groups: 218 participants with HbA1c < 5.7% (group A: non-diabetic), 226 with HbA1c ≥ 5.7% and <6.5% (group B: prediabetic) and 333 with HbA1c ≥ 6.5% (group C: diabetic). Biochemical and hematological parameters were compared among the three groups. An analysis of variance was performed to determine the correlations of the parameters among the groups. The ALB and sodium (Na) levels were significantly lower in group C than in groups A (ALB: 3.8 g/dL vs. 4.1 g/dL, p < 0.0001, Na: 138.4 mmol/L vs. 139.3 mmol/L, p < 0.001) and B (ALB: 3.8 g/dL vs. 4.0 g/dL, p < 0.0001, Na: 138.4 mmol/L vs. 139.6 mmol/L, p < 0.0001), whereas the RDW-standard deviation (RDW-SD) and urea were increased in group C as compared to group A (RDW: 45.8 vs. 43.9 fL, p < 0.0001, urea: 55.6 mg/dL vs. 38.5 mg/dL, p < 0.0001). The mean platelet volume (MPV) was increased in group C as compared to group A (9.3 fL vs. 9.1 fL, p < 0.05, respectively). Τhe increase in RDW-SD in group A as compared to B and C demonstrates the impact of hyperglycemia on red blood cells. Albumin and RDW might improve risk assessment for the development of diabetes. These results highlight the potential role of these parameters as an indication for prediabetes that would alert for measurement of HbA1c.

27 June 2024 in Oxygen
Verified
Journal Article
Open access
PDF file
SIStavroula Ioannidou
Stavroula Ioannidou
ATAthanasia Tsiakalidou
Athanasia Tsiakalidou
KKKONSTANTINA KAZELI
KONSTANTINA KAZELI
AGArgyrios Ginoudis
Argyrios Ginoudis
AFAriadni Fouza
Ariadni Fouza
Evgenia LymperakiEvgenia Lymperaki
Evgenia Lymperaki
Rheumatoid arthritis (RA) is a well-known autoimmune inflammatory disease that affects the diarthrodial joints. Inflammation increases the production of reactive oxygen species (ROS), which may explain why RA is one of the diseases that induce oxidative stress. This study aimed to evaluate the potential differences in biochemical, hematological, and oxidative stress markers in the early stages of RA and after different treatment regimens. The study involved 111 patients, 28 men and 83 women aged 34 to 59 years, who were divided based on their c-reactive protein (CRP) levels into inactive RA patients (IRA) with CRP < 1.3 (n = 57, 22 men and 35 women) and active RA patients (ARA) with CRP ≥ 1.3 (n = 54, 6 men and 48 women). The study participants were divided into two groups, A and B, based on their treatment regimen. Group A, 90% of which were IRA patients, received methotrexate (MTX) monotherapy. Group B, which comprised 90% ARA patients, received a combination of leflunomide, a conventional disease-modifying antirheumatic drug (DMARD), and a biologic DMARD. The hematological, biochemical, oxidative stress, and RA-specific biomarkers were measured twice in groups A and B in the early stage of the disease, before and 3 months post-treatment, using conventional colorimetric, fluorometric, and immunological assays. According to the results of our study, glutathione peroxidase (GPx), ROS, calcium (Ca) and phosphorus (P) ions, vitamin C and D, and lipid profiles could serve as potential diagnostic markers in the early stages of the disease. Both treatment options were equally effective at improving the overall health of the patients. However, treatment resulted in a further increase in ROS levels and a decrease in antioxidant markers.

30 March 2025 in Journal of Xenobiotics
Verified
Journal Article
Open access
PDF file
SIStavroula Ioannidou
Stavroula Ioannidou
AGArgyrios Ginoudis
Argyrios Ginoudis
Kali MakedouKali Makedou
Kali Makedou
Magda TsolakiMagda Tsolaki
Magda Tsolaki
Evgenia LymperakiEvgenia Lymperaki
Evgenia Lymperaki
Mild cognitive impairment (MCI) is recognized as an intermediate stage between normal aging and dementia. Oxidative stress is implicated in the pathophysiology of neurodegenerative diseases, playing a crucial role. This study aimed to investigate the differences in malondialdehyde (MDA) levels in the serum and cerebrospinal fluid (CSF) of patients with MCI compared to FDA-approved biomarkers, based on age, sex, and education level. Participants aged 55–90 years old were categorized into three groups based on FDA-approved biomarkers, especially the CSF Aβ42/Aβ40 ratio and clinical screening assessments: 30 MCI (A+) patients with abnormal CSF Aβ42/Aβ40 ratios (Group A), 30 MCI (A−) patients with normal CSF Aβ42/Aβ40 ratios (Group B), and 30 healthy (A−) participants with normal CSF Aβ42/Aβ40 ratios (Group C). The measurements of CSF FDA-approved biomarkers were performed using an automated immunochemical method (Fujirebio, Inc.), while MDA determination was performed using a competitive inhibition enzyme immunoassay technique (ELK Biotechnology Co., Ltd.). Our results showed that the mean CSF MDA values were significantly lower in group C than in group A (83 ng/mL vs. 130 ng/mL, p = 0.024) and group B (83 ng/mL vs. 142 ng/mL, p = 0.011), respectively. Differences in serum and CSF MDA levels were presented in the study groups based on sex, age, and education level. These findings suggest that lipid peroxidation, as indicated by CSF MDA, could serve as a potential biomarker for the early recognition of MCI.

8 June 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
ATAngelos L.N. Thomas
Angelos L.N. Thomas
MKMaria Karayannopoulou
Maria Karayannopoulou
TATilemahos Anagnostou
Tilemahos Anagnostou
DPDimitra Psalla
Dimitra Psalla
KIKonstantinos Ioannou
Konstantinos Ioannou
DPDimitra Pardali
Dimitra Pardali
In cancer cases, any imbalance between Reactive Oxygen Species (ROS) production and host antioxidant capacity (oxidative stress), during the immediate post-operative period, is involved in cancer cell dissemination (micro-metastases). Surgical trauma is considered the main cause for ROS production during that period. Increased oxidative stress has been found in dogs with mammary neoplasms. Our objective was to investigate the blood oxidant/antioxidant profile in bitches with mammary cancer, during the peri-operative period, hypothesizing that oxidative stress would be further increased after mastectomy. Twelve bitches with mammary cancer and no distant metastases, with a comparable extent of surgical wound and receiving the same anesthetic protocol, were included. Their serum oxidant/antioxidant profile was evaluated chromatometrically using the d-ROMs (Reactive Oxygen Metabolite-derived compounds) and the BAP (biological antioxidant potential) tests, on the 1st day (before/after surgery), and on the 2nd, 3rd and 10th days post-operatively. The ratio of d-ROMs and BAP values (oxidative stress index; OSI) was also calculated. Statistically significant differences (increases) were found only in d-ROMS on the second and third post-operative day compared to the first day (before surgery) of measurement (p = 0.007 and p = 0.002, respectively). Our findings indicate a post-surgical overproduction of ROS and therefore an oxidative stress increase potentially affecting patient outcome.

15 June 2022 in Medicines
Verified
Journal Article
Open access
PDF file
Evgenia LymperakiEvgenia Lymperaki
Evgenia Lymperaki
KKKONSTANTINA KAZELI
KONSTANTINA KAZELI
GVGeorgia Variti
Georgia Variti
MGMagda Gerothanasi
Magda Gerothanasi
AGArgyrios Ginoudis
Argyrios Ginoudis
EVEleni Vagdatli
Eleni Vagdatli
COVID-19 disease is still a major global concern because of its morbidity and its mortality in severe disease. Certain biomarkers including Reactive Oxygen Species (ROS), vitamins, and trace elements are known to play a crucial role in the pathophysiology of the disease. The aim of our study was to evaluate how certain biomarkers, such as ROS, biochemical indicators, trace elements in serum blood of 139 COVID-19 hospitalized patients, and 60 non-COVID cases according to age and sex variations, can serve as the predictors for prognosis of COVID-19 outcome. An attempt of correlating these biomarkers with the severity of the disease as well as with each other is represented. All subjects were hospitalized from April 2021 until June 2021. A statistically significant increase of B12 levels (p = 0.0029) and ROS levels (p < 0.0001) as well as a decrease in albumin and Total Protein (T.P.) levels (p < 0.001) was observed especially in the early stage of the disease before CRP and ferritin elevation. Additionally, a statistically significant increase in ferritin (p = 0.007), B12 (p = 0.035, sALT p = 0.069, Glucose p = 0.012 and urea p = 0.096 and a decrease in Ca p = 0.005, T.P p = 0.052 albumin p = 0.046 between stage B (CRP values 6–30 mg/L) and C (CRP values 30–100 mg/L) was evident. Thus, this study concludes that clinicians could successfully employ biomarkers such as vitamin B12, ROS and albumin as possible prognosis tools for an early diagnosis. In addition, the total biochemical profile can assist in the understanding of the severity of COVID-19 disease, and could potentially lead to a better diet or early pharmaceutical treatment to prevent some of the more acute symptoms.